← Back to all trials
Active Not Recruiting
NCT07728396
A Phase 1 Study to Evaluate the Safety and Immunogenicity of GC4006A in Healthy Adults
Conditions: COVID - 19
Sex: All
Ages: 19 Years – 64 Years
Healthy volunteers: Yes
Phase: PHASE1
Enrollment: 72
Sponsor: GC Biopharma Corp
Location: Korea University Guro Hospital Seoul
Summary
A Phase 1, Randomized, Double-blind, Dose-Escalation, Placebo-Controlled, Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Preventive Vaccine 'GC4006A' in Healthy Adults Aged 19 to 64 Years
Eligibility Criteria
Inclusion Criteria:
* Age 19-64 with written informed consent
* ≥16 weeks since last COVID-19 vaccination
Exclusion Criteria:
* Positive SARS-CoV-2 test (RT-PCR/Rapid Antigen) at screening or randomization
* \
Source: ClinicalTrials.gov (NCT07728396). StuddyBuddy aggregates publicly available trial information.
